Intuitive Surgical, Inc.

🇺🇸NASDAQ Global Select

Articles

43
Show Summary
Show Bulletpoints
Detailed View
Very Bullish +85

Intuitive Announces First Quarter Earnings

📈 Q1 2026 revenue reached $2.77B, up 23% YoY with strong Ion growth.

🛠 Installed base expanded 12% for da Vinci and 22% for Ion systems.

💰 GAAP net income hit $822M as company repurchased $1.1B in stock.

📈 Intuitive Surgical reported first-quarter 2026 revenue of $2.77 billion, a 23% increase from the same period in 2025.

🔼 Worldwide robotic procedures grew approximately 17%, with Ion procedures surging 39% compared to da Vinci's 16% growth.

🛠 The company placed 431 da Vinci surgical systems and 52 Ion endoluminal systems during the quarter, exceeding prior year volumes.

📊 The installed base expanded by 12% for da Vinci systems (now 11,395 units) and 22% for Ion systems (now 1,041 units).

💰 GAAP net income reached $822 million, or $2.28 per diluted share, up from $698 million in the previous year's quarter.

🚀 Da Vinci 5 models accounted for a significant portion of placements, with 232 units deployed compared to 147 last year.

💼 The company repurchased 2.3 million shares of stock for $1.1 billion, reducing its cash holdings by approximately $1.05 billion.

🔧 Instruments and accessories revenue rose 23% to $1.69 billion, driven by increased procedure volume and Ion growth.

⚠️ Operations included a share-based compensation expense of $213 million, with GAAP operating income rising to $855 million.

💵 Intuitive ended the quarter with $7.98 billion in cash, cash equivalents, and investments across its global operations.

🗣️ CEO Dave Rosa highlighted expanded adoption of da Vinci, Ion, and digital platforms as a key performance driver.

🎯 Management aims for worldwide da Vinci procedure growth between 13.5% and 15.5% throughout the full year of 2026.

📉 Expected non-GAAP gross profit margin for 2026 is projected between 67.5% and 68.5% of revenue, including tariff impacts.

📈 Non-GAAP operating expenses are expected to grow between 11% and 14% in 2026 following the current quarter's results.

⚖️ GAAP net income included excess tax benefits of $73 million during the first quarter compared to $145 million in the prior year.

📉 Ion procedures represented the strongest growth segment within the minimally invasive care portfolio for this reporting period.

Bullish Signals
  • Worldwide procedures grew 17%; da Vinci up 16%, Ion surged 39%.
  • Placed 431 da Vinci systems (+64 YoY) and 52 Ion systems (vs. 49).
  • First quarter revenue rose 23% to $2.77B, vs. $2.25B last year.
  • GAAP net income reached $822M ($2.28/share), up from $698M ($1.92/share).
  • Non-GAAP net income hit $901M ($2.50/share), vs. $662M ($1.81/share) last year.
  • Instruments revenue grew 23% to $1.69B, driven by procedure volume growth.
  • Installed base expanded: da Vinci count now 11,395 systems; Ion at 1,041.
  • Repurchased 2.3M shares for $1.1B, showing confidence in long-term value.
Risk Factors
  • Excess tax benefits fell $72M YoY to $73M ($0.20/share).
  • Cash dropped $1.05B in Q1 due to buybacks and M&A.
  • Aggressive stock repurchases reduce liquidity for growth.
  • Margins hit 67.5%–68.5%, including 1% tariff impact.
  • Expenses grow 11%–14%, outpacing 13.5%–15.5% volume growth.
  • Tariffs remain through year-end, risking further profits.
Bullish Signals
  • Intuitive Surgical reported first quarter 2026 worldwide procedures growth of approximately 17%, with da Vinci procedures increasing by 16% and Ion procedures surging by 39%.
  • The Company placed 431 da Vinci surgical systems in the first quarter of 2026, a significant increase from 367 placements in the same period last year, while also placing 52 Ion endoluminal systems compared to 49.
  • First quarter 2026 revenue reached $2.77 billion, representing a robust 23% increase over the $2.25 billion reported in the first quarter of 2025.
  • GAAP net income attributable to Intuitive Surgical rose to $822 million, or $2.28 per diluted share, compared with $698 million, or $1.92 per diluted share, in the prior year period.
  • Non-GAAP net income strengthened to $901 million, or $2.50 per diluted share, up from $662 million, or $1.81 per diluted share, in the first quarter of 2025.
  • Instruments and accessories revenue increased by 23% to $1.69 billion, driven by approximately 16% growth in da Vinci procedure volume and 39% growth in Ion procedure volume.
  • The installed base continued to expand significantly, with the da Vinci surgical system count reaching 11,395 systems and the Ion endoluminal system count growing to 1,041 systems.
  • Intuitive repurchased 2.3 million shares of its common stock for $1.1 billion in the first quarter of 2026, demonstrating confidence in the company's long-term value.
Risk Factors
  • First quarter 2026 excess tax benefits decreased to $73 million ($0.20 per diluted share) from $145 million ($0.40 per diluted share) in the first quarter of 2025, which is a significant year-over-year decline in one-time income support.
  • Cash position ended the first quarter of 2026 at $7.98 billion, representing a decrease of $1.05 billion during the quarter driven primarily by share repurchases and business acquisitions.
  • The company plans to continue aggressive capital deployment with significant cash used for repurchasing common stock, which reduces liquidity available for growth or R&D investment.
  • Management expects non-GAAP gross profit margins in 2026 to be within a range of 67.5% to 68.5%, and this guidance explicitly includes an estimated adverse impact from tariffs amounting to 1.0% of revenue.
  • Operating expenses are expected to grow by 11% to 14% in 2026, which represents a relatively high growth rate compared to the anticipated procedure volume growth of approximately 13.5% to 15.5%.
  • The company's forward guidance assumes tariffs remain in place through the end of the year, indicating ongoing headwinds from trade policy that could negatively impact profitability if additional tariffs are enacted.
Slightly Bullish +25

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

📉 Shares dropped -7.8% last month, underperforming benchmarks.

💵 Reported revenue matched estimates while EPS beat by +12.44%.

🔮 Zacks Rank #3 suggests stock will move in line with market.

⚙ Full-year earnings projected at $10.05, up 12.5% year over year.

📉 Sales growth projected at +15.8% for current quarter.

📉 Intuitive Surgical shares fell -7.8% over the past month, underperforming both the Zacks S&P 500 (-3.3%) and the Medical Instruments industry (-6.4%).

🎯 Analysts are focusing on changes in future earnings projections as the primary driver of fair stock value rather than short-term news or rumors.

💰 The company expects quarterly earnings of $2.08 per share, representing a +14.9% increase from the same quarter last year.

📈 Full-year fiscal earnings consensus is projected at $10.05 (+12.5% YoY), while next-year estimates are set at $11.39 (+13.3% YoY).

📉 The Zacks Consensus estimate changed slightly over the last month, with a minor -0.2% revision for the next fiscal year.

🌐 Based on earnings estimate revisions and other factors, Intuitive Surgical currently holds a Zacks Rank of #3 (Hold).

💵 Reported revenues of $2.87 billion in the last quarter matched consensus estimates exactly but beat EPS expectations by +12.44%.

⚙️ The company has beaten EPS estimates in each of the trailing four quarters and topped revenue estimates three times during that period.

📉 Sales projections indicate +15.8% growth for the current quarter, +14.8% for the current fiscal year, and +12.2% for next fiscal year.

💰 Valuation analysis places Intuitive Surgical at a premium to peers, earning a D grade on the Zacks Value Style Score system.

🔮 A Zacks Rank #3 suggests the stock may perform in line with the broader market in the near term despite the recent price decline.

Bullish Signals
  • Intuitive Surgical expected to post $2.08 EPS, up 14.9% from prior quarter.
  • Full-year consensus estimate of $10.05 EPS reflects 12.5% year-over-year growth.
  • Next fiscal year earnings guidance of $11.39 shows 13.3% increase.
  • Quarterly sales estimate reaches $2.61B, up 15.8% from prior year.
  • Last quarter revenues hit $2.87B, exceeding estimates with strong EPS surprise.
  • Company has beaten EPS estimates for each of trailing four quarters.
  • Revenue estimates were topped three times over last four-quarter period.
  • Fiscal year revenue up 14.8% and next fiscal year growth 12.2%.
  • Long-term earnings trajectory supported by consistent double-digit growth rates.
Risk Factors
  • Intuitive Surgical shares down 7.8% this month.
  • Stock underperforms S&P 500 and Medical Instruments peers.
  • Zacks Rank #3 suggests in-line performance with market.
  • Graded D on Value Style Score indicating overvaluation.
  • Consensus earnings estimate revised down -0.2% recently.
Bullish Signals
  • Intuitive Surgical is expected to post earnings of $2.08 per share for the current quarter, indicating a change of +14.9% from the year-ago quarter.
  • The consensus earnings estimate of $10.05 for the current fiscal year indicates a year-over-year change of +12.5%, signaling sustained growth prospects.
  • For the next fiscal year, the consensus earnings estimate of $11.39 indicates a change of +13.3% from what Intuitive Surgical is expected to report a year ago.
  • The consensus sales estimate of $2.61 billion for the current quarter points to a year-over-year change of +15.8%, demonstrating robust revenue growth.
  • The reported revenues of $2.87 billion in the last quarter represented a year-over-year change of +18.8%, exceeding expectations with an EPS surprise of +12.44%.
  • Intuitive Surgical has beaten consensus EPS estimates in each of the trailing four quarters, showcasing consistent outperformance.
  • The company topped consensus revenue estimates three times over the trailing four-quarter period, indicating strong fundamentals.
  • A year-over-year change of +14.8% in current fiscal year revenue and +12.2% growth in the next fiscal year further supports long-term earnings trajectory.
Risk Factors
  • Shares of Intuitive Surgical have returned -7.8% over the past month, significantly underperforming both the Zacks S&P 500 composite (-3.3%) and the Medical Instruments industry (-6.4%).
  • The stock is rated with a Zacks Rank #3 (Hold), suggesting it may perform in line with the broader market rather than outperform.
  • Intuitive Surgical is graded D on the Zacks Value Style Score, indicating that its stock is trading at a premium to its peers and is considered overvalued based on traditional and unconventional valuation metrics.
  • For the next fiscal year, the consensus earnings estimate has changed by -0.2% over the last month, signaling a slight negative revision in analyst expectations.
Bullish +75

Intuitive Surgical: The Robotic Surgery Leader Still Has Massive Growth Ahead

📈 Initiated as a Buy with a $584.87 target, offering 19% upside potential.

💰 Recurring revenue from consumables and services supports the robust business model.

⚠ Margins face temporary tariff headwinds but are expected to stabilize by 2026.

🚀 Growth driven by global robotics adoption and technological innovation in surgery.

⚡ Key risks include tariff exposure and emerging competition in the sector.

📈 Intuitive Surgical is being initiated with a Buy rating and a $584.87 price target, representing 19% upside potential from current levels.

💰 The company's business model is supported by robust recurring revenues derived from consumables and service contracts.

🤖 Growth expectations are anchored in continued adoption of robotic surgery systems and strategic international market expansion.

⚠️ Operating margins faced temporary headwinds due to tariff pressures and costs associated with launching the Da Vinci 5 system.

📉 Analysts anticipate that operating margins will stabilize by 2026 despite the recent temporary pressure.

⚡ Key risks identified include ongoing exposure to tariffs and the emergence of new competitors in the robotic surgery space.

🏆 Market leadership, technological innovation, and a strong balance sheet are cited as drivers for ISRG's premium valuation.

🛸 While primarily a medical technology company, the investment case is being analyzed within an aerospace and defense research framework due to overlapping technological themes.

👤 The analyst Dhierin-Perkash Bechai runs The Aerospace Forum, which specializes in investment opportunities within aerospace, defense, and airline industries.

📝 Standard disclosure notes that the author has no stock positions or compensation plans related to the companies mentioned in the report.

🚫 Seeking Alpha clarifies that it is not a licensed securities dealer or investment adviser and that past performance does not guarantee future results.

Bullish Signals
  • Initiated Buy with $584.87 target showing 19% upside.
  • Recurring consumables revenues drive robotic surgery growth.
  • Operating margins resilient and expected to stabilize in 2026.
  • Strong balance sheet supports premium valuation and innovation.
Risk Factors
  • Tariffs and Da Vinci 5 rollout pressured margins temporarily.
  • New entrants threaten dominant position in robotic surgery.
  • Ongoing tariff exposure risks future margin stability.
  • Margin compression continues despite stabilization expectations by 2026.
Bullish Signals
  • Intuitive Surgical has been initiated with a Buy rating and a $584.87 price target, reflecting significant 19% upside potential.
  • The company's business model benefits from robust recurring revenues in consumables and services, driving continued growth in robotic surgery adoption and international expansion.
  • Despite temporary margin pressure, Intuitive Surgical's operating margins remained resilient and are expected to stabilize by 2026.
  • ISRG possesses a strong balance sheet that underpins its premium valuation while maintaining market leadership and innovation.
Risk Factors
  • Margins faced temporary pressure from tariffs and the Da Vinci 5 rollout, creating short-term financial headwinds.
  • The company faces significant competition from new entrants in the robotic surgery market which could challenge its dominant position.
  • Tariff exposure remains a key risk that could impact margins if trade policies continue to tighten or expand.
  • While operating margins are expected to stabilize by 2026, this suggests current margin compression is an ongoing concern rather than a resolved issue.